Dark

INO
Inovio Pharmaceuticals, Inc.
stock NASDAQ

At Close

Feb 13, 2026 3:59:30 PM EST

1.62USD+2.215%(+0.04)362,138

0.00Bid 0.00Ask 0.00Spread

Pre-market

Feb 13, 2026 8:31:30 AM EST

1.59USD+0.633%(+0.01)5,540

After-hours

Feb 12, 2026 4:06:30 PM EST

1.57USD-0.946%(-0.02)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 21, 2022

10:05AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 21, 2022 Benzinga

07:35AM EST 10 Biggest Price Target Changes For Friday Benzinga

06:57AM EST B of A Securities Upgrades Inovio Pharmaceuticals to Neutral, Raises Price Target to $10 Benzinga

Dec 14, 2021

08:47AM EST INOVIO Issues Updates For VGX-3100; Long-term Data RTTNews

08:08AM EST INOVIO Highlights Updates On Phase 3 Program For VGX-3100, DNA-based Immunotherapy For Treatment Of Cervical HSIL RTTNews

08:06AM EST INOVIO Highlights Key Updates On Phase 3 Program For VGX-3100, Its DNA-Based Immunotherapy For Treatment Of Cervical HSIL Caused By HPV-16 And/Or HPV-18 Benzinga

08:01AM EST Immunotherapy for the Treatment of Cervical HSIL Caused by HPV-16 and/or HPV-18 PR Newswire

Nov 30, 2021

04:47PM EST INOVIO Says Is 'rapidly moving to evaluate its COVID-19 DNA vaccine candidates INO-4800 and INO-4802 against the emerging B.1.1.529 (Omicron) variant' Benzinga

08:48AM EST INOVIO (INO) said it is rapidly moving to evaluate the company's COVID-19 DNA vaccine candidates INO-4800 and INO-4802 against the emerging Omicron variant. Also, INOVIO has started pre-clinical development of an Omicron-specific DNA vaccine candidate. RTTNews

08:07AM EST INOVIO Says Initiated Pre-clinical Development Of Omicron-specific DNA Vaccine Candidate RTTNews

08:02AM EST INOVIO Announces Strategy to Address Omicron (B.1.1.529) and Future SARS-CoV-2 PR Newswire

Nov 16, 2021

08:06AM EST INOVIO Reports Collab With GuardRX, Geneva University Hospitals For Heterlogous Booster Clinical Trial Of Its Ebola DNA Vaccine Candidate Benzinga

08:04AM EST INOVIO Collaborates With Geneva University Hospitals For Heterologous Booster Trial Of Ebola DNA Vaccine Candidate RTTNews

08:04AM EST Heterologous Booster Clinical Trial of its Ebola DNA Vaccine Candidate, INO-4201 PR Newswire

Nov 15, 2021

08:03AM EST INOVIO to Give Eight Presentations at the 34th International Papillomavirus PR Newswire

Nov 9, 2021

05:40PM EST INOVIO Pharma Filing Shows Registration For $300M At The Market Equity Offering Benzinga

05:14PM EST Inovio Pharmaceuticals Q3 EPS $(0.29) Beats $(0.33) Estimate, Sales $292.00K Miss $970.00K Estimate Benzinga

04:11PM EST INOVIO Q3 Loss/share $0.29 Vs. Profit $0.11 Year Ago RTTNews

04:06PM EST INOVIO Reports Third Quarter 2021 Financial Results PR Newswire

11:42AM EST The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data Benzinga

11:41AM EST INOVIO Reports Receives FDA Authorization To Proceed With INNOVATE Phase 3 Segment For Its COVID-19 Vaccine Candidate In US Benzinga

11:25AM EST Earnings Scheduled For November 9, 2021 Benzinga

08:30AM EST Shares of INOVIO (INO) surged 6% in pre-market trade on Tuesday as the FDA has lifted the partial clinical hold on INNOVATE phase 3 segment. This provides authorization to proceed for INNOVATE phase 3 segment for its COVID-19 vaccine candidate, INO-4800, in the U.S. RTTNews

08:02AM EST INOVIO Gets FDA Authorization To Proceed With INNOVATE Phase 3 Segment For COVID-19 Vaccine Candidate, INO-4800, In U.S. RTTNews

08:01AM EST INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment PR Newswire

Nov 8, 2021

08:29AM EST The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Benzinga

Nov 5, 2021

08:07AM EDT INOVIO Names Gene Kim Chief Corporate Affairs Officer RTTNews

08:01AM EDT INOVIO Expands Executive Leadership to Prepare for Commercial Operations PR Newswire

Nov 3, 2021

09:17AM EDT INOVIO Reports Further Expansion Of Its INNOVATE Phase 3 Trial For COVID-19 DNA Vaccine Candidate With Regulatory Authorization From India Benzinga

08:43AM EDT Inovio Pharmaceuticals, Inc. (INO) Wednesday said it has received authorization from India's Central Drugs Standard Control Organization to proceed with the Phase 3 segment of the global Phase 2/3 trial, INNOVATE, in India for INO-4800. The trial will evaluate the efficacy of INO-4800 in a two-dose regimen of 2.0 mg per dose. RTTNews

08:06AM EDT INOVIO Gets Authorization From India To Proceed With Phase 3 Segment Of INNOVATE Phase 2/3 Trial For INO-4800 RTTNews

08:03AM EDT INOVIO Further Expands INNOVATE Phase 3 Trial for COVID-19 DNA Vaccine PR Newswire

Nov 1, 2021

08:25AM EDT RBC Capital Maintains Sector Perform on Inovio Pharmaceuticals, Lowers Price Target to $6 Benzinga

07:41AM EDT AstraZeneca's Medimmune Terminates DNA Cancer Vaccine Program With Inovio Benzinga

Oct 27, 2021

08:02AM EDT INOVIO to Report Third Quarter 2021 Financial Results on November 9, 2021 PR Newswire

Oct 26, 2021

11:08AM EDT Inovio Pharmaceuticals Granted US Patent Titled 'Cancer vaccines targeting mesothelin and uses thereof' Benzinga

08:13AM EDT INOVIO Completes Enrollment Of Phase 1B Clinical Trial For Its DNA Vaccine Candidate Against Lassa Fever, INO-4500, In West Africa Benzinga

08:02AM EDT INOVIO Completes Enrollment of Phase 1B Clinical Trial for its DNA Vaccine PR Newswire

08:01AM EDT INOVIO Completes Enrollment Of Phase 1B Trial For DNA Vaccine Candidate Against Lassa Fever, INO-4500, In West Africa RTTNews

Oct 21, 2021

12:11PM EDT Inovio Pharmaceuticals Announces Collaboration With Colombia On Memorandum Of Understanding Focusing On Protecting Against COVID-19 And Supporting Broader Health Preparedness Initiatives Benzinga

08:11AM EDT INOVIO Signs MoU With Colombia To Focus On Protecting Against COVID-19 RTTNews

08:03AM EDT Focuses on Protecting Against COVID-19 and Supporting Broader Health Preparedness Initiatives PR Newswire

Oct 12, 2021

08:32AM EDT INOVIO Reports Homologous Boosting Data For COVID-19 RTTNews

08:07AM EDT INOVIO Announces Online Publication: Phase 1 Data Shows COVID-19 DNA Vaccine Candidate INO-4800 Well-tolerated RTTNews

08:05AM EDT INOVIO Announces Online Preprint Publication Of Homologous Boosting Data For COVID-19 DNA Vaccine Candidate, INO-4800 Benzinga

08:01AM EDT INOVIO Announces Online Preprint Publication of Homologous Boosting Data for PR Newswire

Oct 11, 2021

08:40AM EDT INOVIO (INO) said Monday that it has received authorization from Colombia's INVIMA to conduct the phase 3 segment of the company's global Phase 2/3 trial, INNOVATE in Colombia, for INO-4800, its DNA vaccine candidate for COVID-19. RTTNews

08:05AM EDT INOVIO Expands INNOVATE Phase 3 For INO-4800, DNA Vaccine Candidate For COVID-19, To Include Colombia RTTNews

08:02AM EDT INOVIO Expands INNOVATE Phase 3 For INO-4800, Its DNA Vaccine Candidate For COVID-19, To Include Colombia Following Regulatory Authorization Benzinga

08:01AM EDT INOVIO Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate for PR Newswire

Sep 29, 2021

08:03AM EDT INOVIO to Present Three Posters at IDWeek 2021 PR Newswire

Sep 22, 2021

08:03AM EDT INOVIO Gets Regulatory Authorization To Conduct Phase 3 Trial Of COVID-19 DNA Vaccine Candidate, INO-4800, In Mexico RTTNews

08:03AM EDT INOVIO Receives Regulatory Authorization To Conduct Phase 3 Efficacy Trial Of Its COVID-19 DNA Vaccine Candidate, INO-4800, In Mexico Benzinga

08:02AM EDT INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of PR Newswire

Sep 16, 2021

11:36AM EDT Looking Into Inovio Pharmaceuticals's Return On Capital Employed Benzinga

Sep 10, 2021

07:36PM EDT B of A Securities Downgrades Inovio Pharmaceuticals to Underperform, Lowers Price Target to $8 Benzinga

Sep 1, 2021

08:03AM EDT INOVIO to Present at Upcoming Investor Conferences in September PR Newswire

Aug 26, 2021

09:47AM EDT Why Inovio's Stock Is Trading Higher Today Benzinga

08:02AM EDT INOVIO Says Gets Authorization To Conduct Phase 3 Efficacy Trial Of COVID-19 DNA Vaccine Candidate, INO-4800 RTTNews

08:01AM EDT INOVIO Reports Received Authorization To Conduct Phase 3 Efficacy Trial Of COVID-19 DNA Vaccine Candidate, INO-4800 Benzinga

08:01AM EDT INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 PR Newswire

Aug 24, 2021

11:47AM EDT Inovio Pharmaceuticals Granted U.S. Patent Titled 'Multiple tissue layer electroporation applicator and device' Benzinga

Aug 9, 2021

05:21PM EDT Recap: Inovio Pharmaceuticals Q2 Earnings Benzinga

04:09PM EDT Inovio Pharmaceuticals Q2 EPS $(0.39) Misses $(0.25) Estimate, Sales $272.82K Miss $1.21M Estimate Benzinga

04:07PM EDT INOVIO Q2 Loss/share $0.39 Vs. Loss $0.83 Year Ago RTTNews

04:06PM EDT INOVIO Reports Second Quarter 2021 Financial Results PR Newswire

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

08:22AM EDT INOVIO Expands Partnership With Advaccine To Explore RTTNews

08:05AM EDT INOVIO, Advaccine Receive Regulatory Allowance For 2 Heterologous Prime-Boost Clinical Trials In China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate Benzinga

08:03AM EDT INOVIO, Advaccine Receive Regulatory Allowance For Two Heterologous Prime-Boost Clinical Trials In China Using INO-4800 RTTNews

08:02AM EDT Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate PR Newswire

04:11AM EDT Earnings Scheduled For August 9, 2021 Benzinga

Aug 8, 2021

10:11AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 4, 2021

10:22AM EDT INOVIO (INO) said that it has dosed the first phase 2 trial subject in its quest to develop the first vaccine against the Middle East Respiratory Syndrome or MERS. RTTNews

08:58AM EDT INOVIO Doses First Participant In Phase 2 Trial For DNA Vaccine Against Middle East Respiratory Syndrome (MERS) Benzinga

08:02AM EDT INOVIO Doses First Participant In Phase 2 Trial For DNA Vaccine Against Middle East Respiratory Syndrome RTTNews

08:01AM EDT INOVIO Doses First Participant in Phase 2 Trial for its DNA Vaccine Against PR Newswire

Jul 27, 2021

11:13AM EDT Inovio Pharmaceuticals Granted U.S. Patent Titled 'Electroporation device with detachable needle array with lock-out system' Benzinga

Jul 26, 2021

08:01AM EDT INOVIO to Report Second Quarter 2021 Financial Results on August 9, 2021 PR Newswire

Jun 24, 2021

10:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2021 Benzinga

09:49AM EDT Inovio Pharmaceuticals: Return On Capital Employed Insights Benzinga

07:24AM EDT Jefferies Initiates Coverage On Inovio Pharmaceuticals with Hold Rating, Announces Price Target of $9 Benzinga

Jun 8, 2021

02:02PM EDT Inovio Pharmaceuticals Granted U.S. Patent Titled 'Intradermal jet injection electroporation device' Benzinga

11:35AM EDT Inovio Pharmaceuticals Insights: Return On Capital Employed Benzinga

10:34AM EDT Inovio, Advaccine to Share $100M in Cost for Late-Stage COVID-19 Vaccine Trial Benzinga

08:21AM EDT Inovio Pharmaceuticals Inc. (INO) said that it has expanded partnership with Advaccine Biopharmaceuticals Suzhou Co., Ltd. to conduct global phase 3 efficacy trial of COVID-19 DNA vaccine candidate, INO-4800. RTTNews

08:04AM EDT INOVIO Partners With Advaccine To Conduct Phase 3 Trial Of COVID-19 Vaccine Candidate, INO-4800 RTTNews

08:03AM EDT INOVIO Expands Partnership With Advaccine Biopharmaceuticals Suzhou Co. To Evaluate Safety And Efficacy Of INO-4800; Companies Plan To Share Expected $100M Total Cost Equally Benzinga

08:01AM EDT INOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy PR Newswire

Jun 3, 2021

08:04AM EDT Geneos Therapeutics Reports Positive Preliminary Results Of Its Ongoing First-in-human Trial RTTNews

08:02AM EDT Geneos Therapeutics Announces Clinical Updates on Personalized Cancer Vaccine PR Newswire

May 25, 2021

08:02AM EDT INOVIO to Present at the Jefferies 2021 Virtual Healthcare Conference PR Newswire

May 17, 2021

08:03AM EDT INOVIO Announces Appointment Of Roger Dansey To Board RTTNews

08:02AM EDT INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors PR Newswire

May 12, 2021

09:55AM EDT Inovio's Pan-COVID-19 Vaccine Candidate Can Provide Immune Responses Against Variants, Animal Study Shows Benzinga

08:57AM EDT The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron Benzinga

08:18AM EDT Biotechnology company Inovio Pharmaceuticals Inc. (INO) announced Wednesday that its next-generation Pan-SARS-CoV-2 vaccine candidate, INO-4802, induced potent neutralizing antibodies and T cell responses in preclinical models against the original Wuhan strain as well as against B.1.1.7 (UK variant), B.1.351 (South African variant) and P.1. (Brazilian variant). RTTNews

08:05AM EDT INOVIO Reports Its Pan-COVID-19 Vaccine Candidate Induces Broad Immunity Against Major Viral Variants In Preclinical Studies Benzinga

08:02AM EDT INOVIO Says INO-4802 Induces Broad Immunity Against Major Viral Variants In Preclinical Studies RTTNews

08:01AM EDT INOVIO's Pan-COVID-19 Vaccine Candidate (INO-4802) Induces Broad Immunity PR Newswire

May 11, 2021

07:54AM EDT The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings Benzinga

May 10, 2021

10:58PM EDT INOVIO (INO) reported that its first-quarter net loss widened to $54.4 million or $0.27 per share, from $32.5 million or $0.26 per share last year. Analysts polled by Thomson Reuters expected the company to report a loss of $0.18 per share for the first-quarter. Analysts' estimates typically exclude special items. RTTNews

05:15PM EDT Inovio Pharmaceuticals Exec Says The Ex-US Trial For COVID-19 Vaccine Candidate Is Not Impacted By The Current Phase 3 Partial Clinical Hold; Says On Track To Submit All Documents To FDA To Uplift The Clinical Hold Benzinga

04:42PM EDT INOVIO Q1 Total Revenue $371K Vs $1.3 Mln Last Year RTTNews

04:36PM EDT Recap: Inovio Pharmaceuticals Q1 Earnings Benzinga

04:27PM EDT Inovio Pharmaceuticals Q1 EPS $(0.27) Misses $(0.18) Estimate, Sales $371.12K Miss $850.00K Estimate Benzinga

04:07PM EDT INOVIO Q1 Loss/Shr $0.27 Vs Loss $0.26 Last Year RTTNews

04:06PM EDT INOVIO Reports First Quarter 2021 Financial Results PR Newswire

09:58AM EDT Inovio's DNA COVID-19 Vaccine Candidate Triggers Immune Response In Pivotal Study Benzinga

09:16AM EDT Inovio Pharmaceuticals Inc.'s (INO) DNA vaccine candidate for COVID-19, INO-4800, was generally safe, well-tolerated and immunogenic in all studied age groups, as per a phase 2 segment of its phase 2/3 clinical trial. RTTNews

08:04AM EDT INOVIO Announces Data From Phase 2 Segment Of Clinical Trial Evaluating INO-4800 COVID-19 DNA Vaccine; Prelim. Results Showed INO-4800 Was Safe, Well Tolerated And Immunogenic In All Tested Age group Benzinga

08:03AM EDT INOVIO Says INO-4800 Was Shown To Be Safe, Well-tolerated And Immunogenic In All Age Groups RTTNews

08:01AM EDT INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial PR Newswire

04:09AM EDT Earnings Scheduled For May 10, 2021 Benzinga

May 7, 2021

10:06AM EDT Preview: Inovio Pharmaceuticals's Earnings Benzinga

07:40AM EDT The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Benzinga

May 6, 2021

09:58AM EDT Inovio Files For U.S. Patent Titled 'COMBINATION THERAPY TO TREAT BRAIN CANCER' Benzinga

May 5, 2021

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

May 4, 2021

08:03AM EDT INOVIO to Present at Upcoming Investor Conferences in May PR Newswire

Apr 29, 2021

07:50AM EDT Cramer Weighs In On Coinbase, Kellogg And More Benzinga

Apr 27, 2021

08:01AM EDT INOVIO to Report First Quarter 2021 Financial Results on May 10, 2021 PR Newswire

Apr 23, 2021

02:32PM EDT Mid-Afternoon Market Update: Nasdaq Surges 1.5%; EDAP Shares Plunge Benzinga

12:15PM EDT Mid-Day Market Update: Skechers Jumps On Earnings Beat; Inovio Pharmaceuticals Shares Drop Benzinga

10:22AM EDT Mid-Morning Market Update: Markets Rise; Honeywell Beats Q1 Estimates Benzinga

08:45AM EDT Inovio Stock Slumps After Plans To Exclude US For COVID-19 Vaccine Candidate's Global Trial Benzinga

08:32AM EDT INOVIO (INO) said the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense has notified the company that it will discontinue funding for the phase 3 trial for COVID-19 vaccine candidate, INO-4800. JPEO informed INOVIO that the decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. RTTNews

08:29AM EDT Benzinga Pro's Stocks To Watch For Friday, Apr. 23, 2021: TSLA, MRNA, HYLN, SWIM, INO Benzinga

08:09AM EDT INOVIO Plans For Predominantly Ex-U.S. Phase 3 Trial For COVID-19 Vaccine Candidate, INO-4800 RTTNews

08:01AM EDT INOVIO Planning for ex-US Global Phase 3 Trial for INO-4800 PR Newswire

08:01AM EDT INOVIO Reports Is Planning For A Predominantly Ex-US Phase 3 Trial Of Its COVID-19 Vaccine Candidate Benzinga

Apr 15, 2021

10:06AM EDT Inovio Pharmaceuticals Inc. (INO) said that its DNA vaccine candidate for COVID-19, INO-4800, provided broad cross-reactive immune responses in humans against variants of concern. RTTNews

09:54AM EDT Inovio Pharmaceuticals, Inc. (INO) shares are rising more than 15 percent on Thursday morning trade as the biotechnology company announced that its new study of DNA vaccine candidate for COVID-19, INO-4800 induced a robust T cell response against all spike protein variants tested. RTTNews

08:18AM EDT Benzinga Pro's Top 5 Stocks To Watch For Thursday, Apr. 15, 2021: DELL, AEO, GSK, UNH, INO Benzinga

08:09AM EDT INOVIO Announces Results Of Study Focusing On Human Immune Responses Induced By DNA Vaccine Candidate For COVID-19 RTTNews

08:03AM EDT INOVIO's COVID-19 Vaccine Candidate, INO-4800, Provides Broad Cross-reactive PR Newswire

Apr 9, 2021

10:50PM EDT INOVIO INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inovio Pharmaceuticals Inc. - INO Business Wire

07:15AM EDT Cramer Gives His Opinion On Verizon, Boeing And More Benzinga

Mar 23, 2021

10:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2021 Benzinga

07:25AM EDT B of A Securities Initiates Coverage On Inovio Pharmaceuticals with Neutral Rating, Announces Price Target of $13 Benzinga

Mar 15, 2021

08:02AM EDT INOVIO Names Michael Cordera As EVP & General Counsel RTTNews

08:01AM EDT INOVIO Announces the Appointment of Michael Cordera As Executive Vice President PR Newswire

Mar 12, 2021

10:50PM EST & Foti, LLC Continues to Investigate the Officers and Directors of Inovio Pharmaceuticals Inc. - INO PR Newswire

Mar 4, 2021

08:02AM EST INOVIO to Present at Upcoming Investor Conferences in March PR Newswire

Mar 3, 2021

12:13PM EST Geneos Therapeutics Secures $12 Million in Series A1 Financing to Advance PR Newswire

Mar 2, 2021

09:01AM EST Inovio Reports Q4 Earnings Beat, Mixed REVEAL 1 Data And Coronavirus Vaccine Update Benzinga

08:01AM EST The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data Benzinga

05:11AM EST Inovio Pharmaceuticals Awarded U.S. Patent 10,933,130 'Vaccines with interleukin-33 as an adjuvant' Benzinga

Mar 1, 2021

05:00PM EST Inovio Reports Q4 Earnings Beat, Mixed REVEAL 1 Data And Coronavirus Vaccine Update Benzinga

04:54PM EST From INOVIO Earnings Conference Call: Co. Advancing Work To Test Potential Usage Of COVID-19 Vaccine Candidate As A Seasonal Booster Benzinga

04:35PM EST Recap: Inovio Pharmaceuticals Q4 Earnings Benzinga

04:20PM EST Inovio Pharmaceuticals Q4 EPS $(0.14) Beats $(0.22) Estimate, Sales $5.60M Beat $1.11M Estimate Benzinga

04:16PM EST INOVIO Reports Fourth Quarter 2020 and Year-End Financial Results PR Newswire

04:02PM EST INOVIO Reports Results From REVEAL 1 Phase 3 Trial Evaluating VGX-3100 For Treatment Of High-Grade Precancerous Cervical Dysplasia Caused By HPV-16/HPV-18: Trial Achieved Primary, Secondary Efficacy Endpoints Benzinga

04:02PM EST Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18 PR Newswire

04:01PM EST Inovio FY20 EPS $(1.07) vs $(1.21) In FY19, Sales $7.441M vs $4.112M In FY19 Benzinga

03:51AM EST Earnings Scheduled For March 1, 2021 Benzinga

Feb 27, 2021

09:04PM EST The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings Benzinga

Feb 26, 2021

10:50PM EST INOVIO INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Inovio Pharmaceuticals Inc. - INO Business Wire

10:09AM EST Earnings Outlook For Inovio Pharmaceuticals Benzinga

Feb 24, 2021

07:30AM EST The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO Benzinga

07:26AM EST Qiagen, Inovio In Development Pact For VGX-3100 Companion Diagnostics Benzinga

02:20AM EST Inovio Pharmaceuticals Inc. (INO) and Qiagen N.V. (QGEN) announced Wednesday their collaboration to develop next generation sequencing or NGS companion diagnostic for Inovio's VGX-3100 for advanced cervical dysplasia. RTTNews

01:51AM EST INOVIO, QIAGEN Collaborate To Develop Next Generation Sequencing Companion Diagnostic For INOVIO's VGX-3100 RTTNews

01:45AM EST (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasia PR Newswire

Feb 23, 2021

08:11AM EST INOVIO Announces First Subject Dosed On Phase 1B Clinical Trial For Its DNA Vaccine Against Lassa Fever, INO-4500, In West Africa Benzinga

08:04AM EST INOVIO Reports First Dose In Phase 1B Clinical Trial For DNA Vaccine Against Lassa Fever, INO-4500, In West Africa RTTNews

08:02AM EST INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA PR Newswire

Feb 16, 2021

08:03AM EST INOVIO to Report Fourth Quarter and Full Year 2020 Financial Results on March PR Newswire

Feb 12, 2021

10:06AM EST Benzinga's Top Ratings Upgrades, Downgrades For February 12, 2021 Benzinga

06:33AM EST Oppenheimer Initiates Coverage On Inovio Pharmaceuticals with Outperform Rating, Announces Price Target of $35 Benzinga

Feb 10, 2021

09:42AM EST Inovio Pharma Shares Quiet; Earlier 13G Filing From State Street Showed Raised Stake From ~8M Shares To ~8.89M Shares, Or 5.25% Stake Benzinga

Feb 2, 2021

02:27PM EST Inovio Pharmaceuticals shares were trading higher after the company announced it received a U.S. patent for the oral mucosal electroporation device and use of thereof. Benzinga

10:43AM EST ROCE Insights For Inovio Pharmaceuticals Benzinga

08:12AM EST Inovio Pharmaceuticals Awarded U.S. Patent 10,905,870 'Oral mucosal electroporation device and use thereof' Benzinga

Feb 1, 2021

12:10PM EST Mid-Day Market Update: Silver Surges 7%; Concert Pharmaceuticals Shares Plunge Benzinga

Jan 30, 2021

02:40PM EST Robinhood Expands Trading Restrictions To 50 Stocks, Including GameStop, General Motors, Starbucks, Several SPACs Benzinga

Jan 29, 2021

03:40PM EST Robinhood Updates Limitations For Stock Trading Benzinga

Jan 28, 2021

10:43AM EST Looking Into Inovio Pharmaceuticals's Return On Capital Employed Benzinga

Jan 25, 2021

04:02PM EST INOVIO Announces Closing of Public Offering of Common Stock and Full Exercise PR Newswire

Jan 21, 2021

08:05AM EST The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping Benzinga

05:36AM EST INOVIO Priced 17.7M Share Public Offering of Common Stock @$8.50/Share Benzinga

Jan 20, 2021

10:35PM EST Inovio Pharmaceuticals Inc. (INO) said that it has priced an underwritten public offering of 17.70 million shares of its common stock at a public offering price of $8.50 per share. RTTNews

10:10PM EST INOVIO Announces Pricing of Public Offering of Common Stock PR Newswire

04:56PM EST Hearing Inovio Shares For Offering Priced $8.50-$9/Share Benzinga

04:39PM EST INOVIO Announces Proposed Public Offering Of Common Stock RTTNews

04:35PM EST INOVIO Pharma 8-K Shows, In Dec. 2020, Co.'s Planned Development For INO-4800 Was On Partial Clinical Hold, Co. Had Not Commenced Phase 3 Trial Until Resolved With FDA Benzinga

04:34PM EST INOVIO Pharma Reports $150M Common Stock Offering Benzinga

04:31PM EST INOVIO Announces Proposed Public Offering of Common Stock PR Newswire

04:30PM EST INOVIO Pharma Reports $150M Common Stock Offering Benzinga

04:05PM EST Inovio Pharma Filing Shows Registration For Common Stock Offering, No Size Disclosed Benzinga

Jan 6, 2021

10:22AM EST Emerald Bioscience Creates Unique Path to Prevent Blindness Using Patented Synthetic Cannabinoids Benzinga

08:28AM EST Inovio Pharmaceuticals Inc. (INO) on Wednesday announced positive efficacy results for an open-label Phase 2 trial of VGX-3100 to treat HPV-16 and HPV-18-associated vulvar dysplasia. RTTNews

08:03AM EST INOVIO Announces Positive Efficacy Results For An Open-label Phase 2 Trial Of VGX-3100 RTTNews

08:02AM EST INOVIO Reports VGX-3100 Showed Positive Phase 2 Efficacy In Treatment Of Precancerous Vulvar Dysplasia Caused By HPV-16/18 Benzinga

08:01AM EST INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of PR Newswire

Jan 4, 2021

09:25AM EST Inovio Strikes $100M Coronavirus Vaccine Licensing Deal With China's Advaccine Benzinga

08:21AM EST INOVIO, Advaccine Enter Collaboration And License RTTNews

08:07AM EST INOVIO And Advaccine Enter Collaboration And License Agreement For COVID-19 DNA Vaccine Candidate INO-4800 RTTNews

08:02AM EST INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 PR Newswire

08:02AM EST INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, In Greater China Benzinga

Dec 24, 2020

11:05AM EST Inovio Shares Rise On Positive Data For Coronavirus Vaccine Candidate That's Stable At Room Temps Benzinga

10:09AM EST Inovio Pharmaceuticals Inc. (INO) said that phase 1 clinical data from the first cohort of 40 participants for its COVID-19 DNA vaccine candidate, INO-4800, showed that INO-4800 was immunogenic in all vaccinated subjects, effectively generating an immune response of humoral, including neutralizing antibodies, and/or cellular responses. RTTNews

09:20AM EST INOVIO : Phase 1 Data Shows COVID-19 DNA Vaccine Candidate INO-4800 Immunogenic In All Vaccinated Subjects RTTNews

09:17AM EST INOVIO PR Confirms Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet's EClinicalMedicine Benzinga

09:15AM EST INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine PR Newswire

08:07AM EST 'Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial' - The Lancet Benzinga

Dec 15, 2020

09:52AM EST Return On Capital Employed Overview: Inovio Pharmaceuticals Benzinga

08:36AM EST Biotechnology company INOVIO (INO) said Tuesday it will develop DNA-encoded monoclonal antibody or dMAb candidates to treat COVID-19 with funding from the U.S. Defense Advanced Research Projects Agency or DARPA, and the Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense or JPEO-CBRND. RTTNews

08:03AM EST INOVIO To Develop DMAb Candidates To Treat COVID-19 With Funding From DARPA And DoD JPEO-CBRND RTTNews

08:03AM EST COVID-19 with Funding from the Defense Advanced Research Projects Agency (DARPA) and the Department of Defense's (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) PR Newswire

08:02AM EST INOVIO To Develop DNA-Encoded Monoclonal Antibody Candidates To Treat COVID-19 With Funding From DARPA And DoD's Joint Program Executive Office For Chemical, Biological, Radiological And Nuclear Defense Benzinga

Dec 10, 2020

08:48AM EST Biotechnology company INOVIO Pharmaceuticals Inc. (INO) and Advaccine Biopharmaceuticals Suzhou Co., Ltd. said Thursday that the first subject has been successfully dosed in the Phase 2 clinical trial for COVID-19 DNA vaccine candidate, INO-4800, in China. RTTNews

08:02AM EST INOVIO, Advaccine Report First Dosing Of Subject In Phase 2 Trial For COVID-19 DNA Vaccine Candidate INO-4800 In China RTTNews

08:02AM EST INOVIO, Advaccine Report First Dosing Of Subject In Phase 2 Trial For COVID-19 DNA Vaccine Candidate In China Benzinga

08:01AM EST INOVIO and Advaccine Announce First Dosing of Subject in Phase 2 Clinical Trial PR Newswire

Dec 9, 2020

08:48AM EST Biotechnology company Inovio Pharmaceuticals Inc. (INO) said Wednesday that positive Phase 2 efficacy results showed that VGX-3100, the company's lead immunotherapy asset, showed resolution of HPV-16/18-associated precancerous anal lesions or HSIL in 50 percent, or 11 of the 22 subjects, six months following the start of treatment. RTTNews

08:05AM EST INOVIO: VGX-3100 Show Positive Phase 2 Efficacy In Treatment Of Precancerous Anal Dysplasia Caused By HPV-16/18 RTTNews

08:05AM EST INOVIO Announces VGX-3100 Phase 2 Efficacy Results In Treatment Of Precancerous Anal Dysplasia Caused By HPV-16/18; Says Showed Resolution Of HPV-16/18-Associated Precancerous Anal Lesions In 50% Of Subjects Six Months Following Start Of Treatment Benzinga

08:01AM EST INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of PR Newswire

Dec 7, 2020

08:15AM EST INOVIO Doses First Subject In Phase 2 Clinical Trial Of RTTNews

08:05AM EST INOVIO Doses First Subject In Phase 2 Clinical Trial Evaluating DNA Medicine INO-4800 RTTNews

08:02AM EST INOVIO Doses First Subject In Phase 2 Segment Of INNOVATE Phase 2/3 Clinical Trial For INO-4800 DNA Medicine To Prevent COVID-19 Benzinga

08:01AM EST INOVIO Doses First Subject in Phase 2 Segment of its INNOVATE Phase 2/3 PR Newswire

Dec 6, 2020

08:41AM EST Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace Benzinga

Dec 5, 2020

09:01AM EST Emerald Bioscience Creates Unique Path to Prevent Blindness Using Patented Synthetic Cannabinoids Benzinga

Dec 4, 2020

10:01AM EST Return On Capital Employed Overview: Inovio Pharmaceuticals Benzinga

Dec 3, 2020

03:34PM EST Inovio Strikes Coronavirus Vaccine Manufacturing Deal With Kaneka Unit Benzinga

08:31AM EST Inovio (INO) said that it has expanded global manufacturing consortium for its COVID-19 vaccine candidate INO-4800 with addition of Kaneka Eurogentec S.A. Terms of the agreement were not disclosed. RTTNews

08:08AM EST INOVIO Expands Manufacturing Consortium For COVID-19 Vaccine Candidate INO-4800 With Addition Of Kaneka RTTNews

08:02AM EST INOVIO Expands Global Manufacturing Consortium For Its COVID-19 Vaccine PR Newswire

Nov 23, 2020

08:08AM EST INOVIO Announces Dosing of First Subject in Phase 1/2 Clinical Trial for INO-3107, its DNA Medicine to Treat a Rare Disease Recurrent Respiratory Papillomatosis Benzinga

08:02AM EST INOVIO Announces Dosing Of First Subject In Phase 1/2 Clinical Trial For INO-3107 RTTNews

08:01AM EST INO-3107, its DNA Medicine to Treat a Rare Disease Recurrent Respiratory Papillomatosis (RRP) PR Newswire

Nov 20, 2020

08:36AM EST INOVIO Presents Data From Combination Trial Of INO-5401 RTTNews

08:04AM EST INOVIO To Present Data From Novel Combination Trial Of DNA Medicines INO-5401 And INO-9012 Plus PD-1 Inhibitor Libtayo RTTNews

08:03AM EST INOVIO Highlights Presentation Of Clinical Results Of Its DNA Medicines INO-5401 + INO-9012 In Novel Combination With PD-1 Inhibitor Libtayo For Treatment Of Newly Diagnosed Glioblastoma Multiforme At Society For Neuro-Oncology 2020 Annual Meeting Benzinga

08:01AM EST Novel Combination with PD-1 Inhibitor Libtayo(r) (cemiplimab) in the Treatment of Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 2020 Annual Meeting PR Newswire

Nov 19, 2020

02:45PM EST Inovio Pharmaceuticals Option Alert: Feb 19 $20 Calls Sweep (34) near the Ask: 588 @ $1.15 vs 5131 OI; Ref=$11.02 Benzinga

Nov 17, 2020

05:42PM EST Inovio Analyst: COVID-19 Competition Could Be Too Great Benzinga

10:58AM EST Roth Capital Downgrades Inovio Pharmaceuticals to Sell, Announces $8 Price Target Benzinga

Nov 16, 2020

01:11PM EST Yahoo Finance Trending Stocks For Monday, Nov. 16, 2020: MRNA, WMT, SPCE, BA, PFE, JD, ATHE, TSM, BNTX, TGT, NVAX, HDS, INO, IBIO, XOM, MU, PANW, HPR, TSN, CCL, CAN, GP, BBVA, MMEDF, WWR, UBER, O, RCL, RAPT Benzinga

10:08AM EST Shares of Inovio Pharmaceuticals, Inc. (INO) are climbing more than 4% Monday morning after the company said it has received clearance from the FDA to start Phase 2/3 study of its Covid-19 vaccine candidate, INO-4800. RTTNews

08:24AM EST FDA Lifts Partial Clinical Hold On Inovio's Phase 2 Investigational Coronavirus Vaccine Study Benzinga

07:17AM EST Biotechnology company Inovio Pharmaceuticals Inc. (INO) announced Monday that it has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with the Phase 2 segment of its planned Phase 2/3 clinical trial for INO-4800, its COVID-19 vaccine candidate. RTTNews

07:03AM EST INOVIO Begins Phase 2 Segment Of Phase 2/3 Clinical Trial For COVID-19 DNA Vaccine Candidate, INO-4800 RTTNews

07:03AM EST INOVIO Announces Initiation of Phase 2 Segment of its Phase 2/3 Clinical Trial for its COVID-19 DNA Vaccine Candidate, INO-4800; Trial Will Be Funded by the U.S. Department of Defense Benzinga

07:01AM EST for its COVID-19 DNA Vaccine Candidate, INO-4800; Trial Will Be Funded by the U.S. Department of Defense PR Newswire

Nov 10, 2020

09:31AM EST Benzinga's Top Upgrades, Downgrades For November 10, 2020 Benzinga

07:35AM EST Roth Capital Upgrades Inovio Pharmaceuticals to Neutral Benzinga

Nov 9, 2020

05:08PM EST Inovio Pharmaceuticals On INO-4800 Says Phase 1 Data Publication Through A Peer-Review Process Is Expected In Coming Weeks Benzinga